NDAORALTABLETPriority Review
Approved
Dec 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Priority Review
ALDOMET (methyldopa) by Merck & Co. is clinical pharmacology methyldopa is an aromatic-aminoacid decarboxylase inhibitor in animals and in man. Approved for hypertension. First approved in 1962.
Drug data last refreshed 20h ago
Mechanism of Action
CLINICAL PHARMACOLOGY Methyldopa is an aromatic-aminoacid decarboxylase inhibitor in animals and in man. Although the mechanism of action has yet to be conclusively demonstrated, the antihypertensive effect of methyldopa probably is due to its metabolism to alpha-methylnorepinephrine, which then…
Worked on ALDOMET at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.